Skip To Main Content
Babar Bashir on Muck Rack

Babar Bashir

As seen in: Future Medicine, Pakistan Journal of Medical Research
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Babar

Contact Babar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Pancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape

|
By Babar Bashir, Adam Mueller
Improvement in treatment outcomes for pancreatic adenocarcinoma (PA) has been substantial since 1980s, owing in large part to improved operative mortality rates of < 3%1 and to the advent of effective chemotherapy and radiotherapy approaches.2-4 As Jiang et al5 illustrate in their accompanying review, the effectiveness of adjuvant chemotherapy has significantly improved to an impressive median overall survival (mOS) of 54.4 months with modified (m)folinic acid, fluorouracil, irinotecan, and...
Open in Who Shared Issue with article?

Pancreatic Adenocarcinoma: An Evolving Yet Unimpressive Treatment Landscape

|
By Babar Bashir, Adam Mueller
| ascopubs.org
Improvement in treatment outcomes for pancreatic adenocarcinoma (PA) has been substantial since 1980s, owing in large part to improved operative mortality rates of < 3%1 and to the advent of effective chemotherapy and radiotherapy approaches.2-4 As Jiang et al5 illustrate in their accompanying review, the effectiveness of adjuvant chemotherapy has significantly improved to an impressive median overall survival (mOS) of 54.4 months with modified (m)folinic acid, fluorouracil, irinotecan, and...
Open in Who Shared Issue with article?

Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1 | Immunotherapy

|
By Adam Snook, Babar Bashir, Daniel S Lefler
| Future Medicine Verified
DS Lefler has no conflicts to disclose. AE Snook is a consultant for Targeted Diagnostics and Therapeutics Inc., which provided research funding that, in part, supported this work and has a license to commercialize inventions related to this work. AE Snook was supported by the Defense Congressionally Directed Medical Research Programs (#W81XWH-19-1-0263), West Pharmaceutical Services Inc., the Courtney Ann Diacont Memorial Foundation, and Lorraine and David Swoyer.
Open in Who Shared Issue with article?
See all 5 licensed articles (6 Total)